EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Jialiang Zhao,Xiaoxin Li,Shibo Tang,Gezhi Xu,Xun Xu,Feng Zhang,Meixia Zhang,Jila Shamsazar,Stefan Pilz,Annette Nieweg

DOI: https://doi.org/10.1007/s40259-014-0106-1

2014-01-01

Abstract:Purpose To evaluate the efficacy and safety of monthly ranibizumab 0.5 mg in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD). Methods A 12-month open-label single-arm multicenter phase III study that included treatment-naïve (study eye) patients with primary/recurrent subfoveal CNV secondary to AMD. Patients ( N = 114) aged ≥50 years with best-corrected visual acuity (BCVA) of 73–24 letters were treated with monthly ranibizumab for 12 months. Main outcomes were mean BCVA change from baseline to month 4 (primary endpoint) and over time to month 12, effects of ranibizumab treatment on retinal structure (months 4 and 12), and safety. Results Ranibizumab led to significant improvements in mean BCVA ± standard error (SE) at both months 4 and 12 versus baseline (+9.5 ± 1.10 letters, 95 % confidence interval [CI] 7.3–11.7, and +12.7 ± 1.14 letters, 95 % CI 10.4–14.9, respectively, both P < 0.0001). Ranibizumab prevented loss of vision (≥0 letters BCVA gain) in 91.2 % of patients. Mean central retinal thickness ± SE reduced from baseline to month 12 (−119.9 ± 12.97 µm, 95 % CI −145.59 to −94.20, P < 0.0001). No new safety findings were reported in this study. Conclusion Ranibizumab administered monthly over 12 months was effective in improving BCVA and was well-tolerated in Chinese nAMD patients.